StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a report published on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Trevena Trading Up 8.4 %
TRVN stock opened at $4.01 on Friday. Trevena has a 12 month low of $3.35 and a 12 month high of $25.75. The company has a 50-day moving average price of $2.86 and a 200 day moving average price of $1.25. The stock has a market cap of $73.55 million, a PE ratio of -1.50 and a beta of 1.03.
Trevena (NASDAQ:TRVN – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.36. The firm had revenue of $0.33 million for the quarter.
Institutional Investors Weigh In On Trevena
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Read More
- Five stocks we like better than Trevena
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Conference Calls and Individual Investors
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.